Across TCGA pan-cancer cohorts, TRAV37 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of TRAV37’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where TRAV37 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRAV37 is over-expressed in tumor.
STAD and KIRC are the cancer types where TRAV37 tumor–normal differential expression is most reproducible.